Moxidectin is under clinical development by Medicines Development for Global Health and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Moxidectin’s likelihood of approval (LoA) and phase transition for Helminthiasis (Parasitic Worm Infestation) took place on 15 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Moxidectin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Moxidectin overview

Moxidectin is a semisynthetic derivative of nemadectin and acts as an anthelmintic agent. It is formulated as tablets for oral route of administration. Moxidectin is indicated for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older. Moxidectin is under investigation for the treatment of scabies, onchocerciasis in children, soil-transmitted helminths, strongyloides, lymphatic filariasis and head lice.

Medicines Development for Global Health overview

Medicines Development for Global Health (MDGHL) is an independent biopharmaceutical company that strives to develop and commercialize medicines and vaccines for unmet medical needs. The company’s pipeline clinical programs include Moxidectin, which is being developed for the treatment of river blindness and scabies; and RV-3-BB rotavirus vaccine, for prevention of rotavirus gastroenteritis in infants and neonates. It is also developing products which are in Phase I and II clinical development, for soil-transmitted helminthes, strongyloides and lymphatic filariasis. MDGHL is headquartered in Melbourne, Victoria, Australia.

Quick View Moxidectin LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Moxidectin
Administration Pathway
  • Oral
Therapeutic Areas
  • Dermatology
  • Infectious Disease
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.